[96] [97] Novo Nordisk failed to pay a required patent maintenance fee, and their patent on the chemical structure of the drug expired in 2020
Novo appointed a new CEO in July of this year
7 PIONEER 7 The PIONEER 7 trial, like PIONEER 3, compared oral semaglutide against 100-mg sitagliptin, although this trial differs in that it allowed for flexible dose adjustments of oral semaglutide
Others report new rashes or worsening itch in the first few weeksthough these often resolve over time
At Week 26, the primary HbA1c endpoint was missing for 5.6%, 4.2% and 2.5% of patients randomized to placebo, liraglutide 1.8 mg and semaglutide tablets 14 mg, respectively
Notably, semaglutide lowers glucose levels in hyperglycemia without causing hypoglycemia, making it a preferred treatment for diabetes mellitus [1] [Figure 2]